OTCMKTS:MBGNF

Med BioGene Stock Forecast, Price & News

$0.12
0.00 (0.00 %)
(As of 09/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.12
$0.12
50-Day Range
$0.11
$1.00
52-Week Range
$0.04
$1.00
Volume501 shs
Average Volume5,203 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MBGNF News and Ratings via Email

Sign-up to receive the latest news and ratings for Med BioGene and its competitors with MarketBeat's FREE daily newsletter.


About Med BioGene

Med BioGene, Inc. operates as a life science company. The firm engages in the development and commercialization of genomic-based clinical laboratory diagnostic tests. It focuses on managing the license and rights for GeneFx Lung, prognostic genomic-based test for non-small-cell lung cancer. The company was founded on April 28, 2006 and is headquartered in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Med BioGene (OTCMKTS:MBGNF) Frequently Asked Questions

What stocks does MarketBeat like better than Med BioGene?

Wall Street analysts have given Med BioGene a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Med BioGene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Med BioGene?

Med BioGene saw a decline in short interest in August. As of August 13th, there was short interest totaling 1,000 shares, a decline of 61.5% from the July 29th total of 2,600 shares. Based on an average trading volume of 6,700 shares, the short-interest ratio is currently 0.1 days.
View Med BioGene's Short Interest
.

How were Med BioGene's earnings last quarter?

Med BioGene Inc. (OTCMKTS:MBGNF) posted its earnings results on Friday, November, 29th. The company reported ($0.01) earnings per share for the quarter.
View Med BioGene's earnings history
.

How has Med BioGene's stock price been impacted by Coronavirus?

Med BioGene's stock was trading at $0.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MBGNF shares have increased by 202.8% and is now trading at $0.1211.
View which stocks have been most impacted by COVID-19
.

Who are Med BioGene's key executives?

Med BioGene's management team includes the following people:
  • Iain Weir-Jones, Chairman & Chief Executive Officer
  • Ibrahim Ghobrial, Chief Financial Officer & Secretary

Who are some of Med BioGene's key competitors?

What is Med BioGene's stock symbol?

Med BioGene trades on the OTCMKTS under the ticker symbol "MBGNF."

How do I buy shares of Med BioGene?

Shares of MBGNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Med BioGene's stock price today?

One share of MBGNF stock can currently be purchased for approximately $0.12.

What is Med BioGene's official website?

The official website for Med BioGene is www.medbiogene.com.

Where are Med BioGene's headquarters?

Med BioGene is headquartered at 598 East Kent Avenue South, Vancouver, BC V5X.

How can I contact Med BioGene?

Med BioGene's mailing address is 598 East Kent Avenue South, Vancouver, BC V5X. The company can be reached via phone at (604) 732-7332.


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.